生物制剂治疗中重度斑块状银屑病及关节病型银屑病的进展  

Biological agents in the treatment of moderate to severe plaque psoriasis and psoriatic arthritis

作　　者：高蓉[1] 张兰 李政霄[1] Gao Rong;Zhang Lan;Li Zhengxiao(Department of Dermatology,The Second Affiliated Hospital of Xi′an Jiaotong University,Xi′an 710004,China;Department of Dermatology,East Hospital of the First Affiliated Hospital of Xi′an Jiaotong University,Xi′an 710089,China)

机构地区：[1]西安交通大学第二附属医院皮肤病院,西安710004 [2]西安交通大学第一附属医院东院皮肤科,西安710089

出　　处：《中华皮肤科杂志》2022年第1期72-75,共4页Chinese Journal of Dermatology

摘　　要：银屑病是一种免疫介导的慢性复发性炎症性疾病,针对其发病机制中细胞因子及受体的生物制剂近年成为银屑病重要的治疗手段。随着司库奇尤单抗(secukinumab)和乌司奴单抗(ustekinumab)等生物制剂在我国陆续上市,生物制剂在银屑病治疗中的应用将越来越普遍。本文综述不同生物制剂治疗中重度斑块状银屑病及关节病型银屑病的疗效及个体化用药选择,以期为医师临床用药提供参考。Psoriasis is an immune-mediated chronic recurrent inflammatory disease,and biological agents targeting cytokines and their receptors involved in its pathogenesis have become an increasingly important option for its treatment in recent years.With the successive appearance of biological agents such as secukinumab and ustekinumab on the market in China,the use of biologics will become increasingly common in the treatment of psoriasis.This review summarizes the efficacy of different biological agents and individualized drug selection in the treatment of moderate to severe plaque psoriasis and psoriatic arthritis,with a view to providing a reference for physicians in clinical practice.

关 键 词：银屑病 生物制剂 肿瘤坏死因子Α 白细胞介素类 治疗结果 中重度斑块状银屑病 关节病型银屑病 

分 类 号：R758.63[医药卫生—皮肤病学与性病学]